On Aug. 2, 2018, hundreds of patients and their families, U.S. Food and Drug Administration (FDA) staff, industry leaders, and researchers convened in Washington, D.C. to participate in the externally-ledﾠJuvenile Idiopathic Arthritis (JIA) Patient-Focused Drug Development meeting.